Novartis suspends 24,000-patient elinogrel trial in chronic CHD
This article was originally published in Scrip
Novartis has "suspended indefinitely" a planned 24,000-patient Phase III study in chronic coronary heart disease (CHD) of elinogrel, the antiplatelet candidate that it licensed for up to $575 million through a deal with Portola Pharmaceuticals in 2009.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.